Antibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 17-5499-42 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- TSLP Receptor Monoclonal Antibody (eBio1A6 (1A6)), APC, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The eBio1A6 monoclonal antibody reacts with human thymic stromal-derived lymphopoietin receptor (TSLPR). TSLPR is an approximately 50 kDa protein with significant similarity to the common gamma-chain. TSLPR complexes with IL-7R alpha (CD127) to form the high affinity receptor that binds thymic stromal-derived lymphopoietin (TSLP). Human TSLPR is expressed by monocytes and CD11c+ dendritic cells, and TSLP binding induces the expression of the Th2 cell-attracting chemokines CCL17 and CCL22. Furthermore, the TSLPR-induced activation of dendritic cells indirectly results in the increased secretion of Th cytokines IL-4, -5 and -13, which may be necessary for the regulation of CD4+ T cell homeostasis. In mice, deficiency of TSLPR has no effect on lymphocyte numbers, whereas double deficiency of TSLPR and common gamma-chain results in fewer lymphocytes than seen in mice deficient in the common gamma-chain alone. The eBio1A6 monoclonal antibody is able to cross-block binding of another anti-human TSLPR monoclonal antibody, 1D8. Applications Reported: This eBio1A6 (1A6) antibody has been reported for use in flow cytometric analysis. Applications Tested: This eBio1A6 (1A6) antibody has been pre-titrated and tested by flow cytometric analysis of TSLPR transfected cells. This can be used at 5 µL (0.06 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- eBio1A6 (1A6)
- Vial size
- 100 Tests
- Concentration
- 5 µL/Test
- Storage
- 4° C, store in dark, DO NOT FREEZE!
Submitted references Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
Wu SC, Li LS, Kopp N, Montero J, Chapuy B, Yoda A, Christie AL, Liu H, Christodoulou A, van Bodegom D, van der Zwet J, Layer JV, Tivey T, Lane AA, Ryan JA, Ng SY, DeAngelo DJ, Stone RM, Steensma D, Wadleigh M, Harris M, Mandon E, Ebel N, Andraos R, Romanet V, Dölemeyer A, Sterker D, Zender M, Rodig SJ, Murakami M, Hofmann F, Kuo F, Eck MJ, Silverman LB, Sallan SE, Letai A, Baffert F, Vangrevelinghe E, Radimerski T, Gaul C, Weinstock DM
Cancer cell 2015 Jul 13;28(1):29-41
Cancer cell 2015 Jul 13;28(1):29-41
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE, Weinstock DM
Blood 2012 Oct 4;120(14):2843-52
Blood 2012 Oct 4;120(14):2843-52
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of human TSLP Receptor-transfected cells with Mouse IgG2a K Isotype Control APC (Product # 17-4724-81) (blue histogram) or Anti-Human TSLP Receptor APC (purple histogram). Total viable cells were used for analysis.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL